musclemania70
New member
<p style="line-height: 15pt;"><span style="font-family: 'Arial','sans-serif'; color: black;">Stanford University is offering free cystic fibrosis genotyping of the CFTR gene to eligible non-Caucasian, non-Hispanic CF patients. This clinical service is being funded by the CF Foundation (CFF), a nonprofit donor-supported organization that funds and accredits CF-related programs and research.
<p style="line-height: 15pt;"><span style="font-family: 'Arial','sans-serif'; color: black;"> Genotyping in the form of DNA sequencing is being made available at no cost to CF patients in the United States who have <strong><span style="font-family: 'Arial','sans-serif'; color: #333399;">African, Native American, Asian, East Indian or Middle Eastern</strong><span style="font-family: 'Arial','sans-serif'; color: black;"> backgrounds. The genotypes of these patients, as a group, are currently under-ascertained. The goal of this project is to determine the type and frequency of CF mutations prevalent in these individuals in order to better inform the composition of future CFTR mutation testing methods and/or panels. These new testing approaches or panels have the goal of improving diagnostic sensitivity and of optimizing patient treatments and health outcomes.<span style="font-family: 'Arial','sans-serif'; color: #7d7d7d; font-size: 11pt;">
<p style="line-height: 15pt;"><span style="font-family: 'Arial','sans-serif'; color: black;"> Eligible patients are those with zero or only one known CFTR mutation(s) who fall in the groups stated above in the CF Foundation Patient Registry. Patients who decide to participate will be asked to come in to their CF Center for a single blood draw. This blood sample will be sequenced for CF mutations in the clinical diagnostic laboratory at Stanford University as part of routine medical care. This clinical testing is provided at no cost. Results of these tests are confidential and will be provided only to the CF Center, who will then discuss the results with the patient. There is a chance that a patient’s mutations will remain unidentified after DNA sequencing. The project is not offering financial compensation to participants but the genotyping results being provided may help inform medical care and counseling.
<p style="text-align: center; line-height: 15pt;" align="center"><strong><span style="font-family: 'Arial','sans-serif'; color: #333399;">If you are interested in participating in this project or</strong><span style="font-family: 'Arial','sans-serif'; color: black;"><strong><span style="font-family: 'Arial','sans-serif'; color: #333399;">if you would like to learn more, please contact:</strong><span style="font-family: 'Arial','sans-serif'; color: black;">Lynn Pique, Project Coordinator, Stanford University,working with Dr. Iris SchrijverPhone: (650) 736-1761Fax: (650) 498-2677Email: <strong><span style="text-decoration: underline;"><span style="font-family: 'Arial','sans-serif'; color: #333399;"><a href="mailto:lmpique@stanford.edu"><span style="color: #333399;">lmpique@stanford.edu</a></strong>
<p style="line-height: 15pt;"><span style="font-family: 'Arial','sans-serif'; color: black;"> Genotyping in the form of DNA sequencing is being made available at no cost to CF patients in the United States who have <strong><span style="font-family: 'Arial','sans-serif'; color: #333399;">African, Native American, Asian, East Indian or Middle Eastern</strong><span style="font-family: 'Arial','sans-serif'; color: black;"> backgrounds. The genotypes of these patients, as a group, are currently under-ascertained. The goal of this project is to determine the type and frequency of CF mutations prevalent in these individuals in order to better inform the composition of future CFTR mutation testing methods and/or panels. These new testing approaches or panels have the goal of improving diagnostic sensitivity and of optimizing patient treatments and health outcomes.<span style="font-family: 'Arial','sans-serif'; color: #7d7d7d; font-size: 11pt;">
<p style="line-height: 15pt;"><span style="font-family: 'Arial','sans-serif'; color: black;"> Eligible patients are those with zero or only one known CFTR mutation(s) who fall in the groups stated above in the CF Foundation Patient Registry. Patients who decide to participate will be asked to come in to their CF Center for a single blood draw. This blood sample will be sequenced for CF mutations in the clinical diagnostic laboratory at Stanford University as part of routine medical care. This clinical testing is provided at no cost. Results of these tests are confidential and will be provided only to the CF Center, who will then discuss the results with the patient. There is a chance that a patient’s mutations will remain unidentified after DNA sequencing. The project is not offering financial compensation to participants but the genotyping results being provided may help inform medical care and counseling.
<p style="text-align: center; line-height: 15pt;" align="center"><strong><span style="font-family: 'Arial','sans-serif'; color: #333399;">If you are interested in participating in this project or</strong><span style="font-family: 'Arial','sans-serif'; color: black;"><strong><span style="font-family: 'Arial','sans-serif'; color: #333399;">if you would like to learn more, please contact:</strong><span style="font-family: 'Arial','sans-serif'; color: black;">Lynn Pique, Project Coordinator, Stanford University,working with Dr. Iris SchrijverPhone: (650) 736-1761Fax: (650) 498-2677Email: <strong><span style="text-decoration: underline;"><span style="font-family: 'Arial','sans-serif'; color: #333399;"><a href="mailto:lmpique@stanford.edu"><span style="color: #333399;">lmpique@stanford.edu</a></strong>